期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

氯吡格雷抵抗研究的新分歧 被引量：5

下载PDF
导出
摘要 双联抗血小板治疗是急性冠状动脉综合征（ACS）和经皮冠状动脉介入（PCI）的标准化治疗[1]。但尽管双重抗血小板治疗,仍有患者发生心血管事件,最严重的是支架内血栓形成[2]。最近新发现氯吡格雷抵抗是PCI术中无血流的机制之一[3],血栓事件发生后的病死率为15%～45%,再梗死率为60%～70%。
作者 孟晓冬 王燕慧 张灏
机构地区 甘肃省第二人民医院心内科 甘肃省第二人民医院重症医学科
出处 《国际检验医学杂志》 CAS 2013年第15期1990-1992,共3页 International Journal of Laboratory Medicine
基金 甘肃省卫生行业科研计划项目(2010-652)
关键词 氯吡格雷抵抗 抗血小板治疗 急性冠脉综合征 经皮冠脉介入治疗
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献31

  • 1Vlachojannis GJ,Dimitropoulos G, Alexopoulos D. Clopidogrel re- sistance:current aspects and future directions[J]. Hellenic J Car- diol, 2011,52(3) .. 236-245.
  • 2Bozbeyoglu E,Satilmis S,Aksu H, et al. Impact of clopidogrel re- sistance on ST-segment resolution and no-reflow in acute myocar- dial infarction with ST-elevation patients treated with a primary percutaneous coronary intervention[J]. Coron Artery Dis, 2012, 23(8) 523-527.
  • 3Alexander SP,Mathie A,Peters JA. Guide to Receptors and Chan-ne|s (GRAC), 4th Edition[J]. Br J Pharmacol, 2009,158 ( Suppl 1) :S1-254.
  • 4Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy[J]. Am J Cardiol, 2009,103 (3 Suppl) = 27A-34A.
  • 5Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial[J]. JA MA,2011,305(11) :1097 1105.
  • 6Cuisset T, Frere C, Quilici J, et al. Role of the T744C polymor phism of the P2Y12 gene on platelet response to a 600 mg loading dose o[ clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome[J]. Thromb Res, 2007, 120 (6): 893 899.
  • 7Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascu- lar events in patients with clopidogrel resistance: a multicenter randomized prospective study[J]. J Am Coil Cardiol, 2008, 51 (14):1404 1411.
  • 8Dupont AG, Gabriel DA, Cohen MG. Antiplatelet therapies and the role ot antiplatelet resistance in acute coronary syndrome[J]. Thromb Res,2009,124(1) =6-13.
  • 9Serebruany V,Cherala G,Williams C,et al. Association of platelet responsiveness with clopidogrel metabolism:role of compliance in the assessment of "resistance" [J]. Am Heart J, 2009, 158 ( 6 ) : 925-932.
  • 10王燕慧,张灏.他汀类药物与氯吡格雷相互作用争议的现状[J].国际心血管病杂志,2011,38(2):104-107. 被引量：20

二级参考文献52

  • 1任艺虹,盖鲁粤,杨庭树,王洪叶,王禹,邢攸红,林琳,刘春雪.改良血栓弹力图法和流式细胞测定技术对血小板活性抑制程度的比较研究[J].中华心血管病杂志,2007,35(4):366-367. 被引量：37
  • 2Porto I, Van Gaal W, Banning A. Impact of the elevation of biochemical markers of myocardial damage on long term mortality after percutaneous coronary intervention: results of theCK MBand PCI study[J]. Eur Heart J, 2005,26(20): 2206-2207.
  • 3Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction[J]. J Am Coll Cardiol, 2009,54 (23) : 2157-2163.
  • 4Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early pereutaneous coronary intervention: results of the ARMYDA ACS randomized trial [J]. J Am Coll Cardiol, 2007,49(12) :1272- 1278.
  • 5Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention : results of the ARMYDA RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial [J]. J AmCollCardiol, 2009,54(6):558 -565.
  • 6Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives[J]. J Am Coll Cardiol, 2007,49(14) :1505 -1516.
  • 7Marian AJ. Cytochrome p-450 polymorphisms and response to clopidogrel[J]. Curr Atheroscler Rep, 2009,11(3):157-160.
  • 8Neubauer H, Gtinesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of elopidogrel on platelet function-a flow cytometry study[J]. Eur Heart J, 2003,24(19) : 1744-1749.
  • 9Brophy JM, Babapulle MN, Costa V, et al. A pharmacoe pidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention[J]. Am Heart J, 2006,152(2) :263 -269.
  • 10Saw J, Brennan DM, Steinhubl SR,et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial[J]. J Am Coll Cardiol, 2007,50(4):291-295.

共引文献27

同被引文献88

  • 1苏冠华,王朝晖.血小板膜GPⅡb/Ⅲa基因多态性与冠心病[J].心血管病学进展,2006,27(z1):14-16. 被引量：3
  • 2郝盼盼,陈玉国,张运.氯吡格雷抵抗相关因素的研究进展[J].心血管病学进展,2009,30(6):991-994. 被引量：21
  • 3吴小利,李健,王成彬.抗血小板药物新进展[J].临床检验杂志（电子版）,2012,1(4):221-227. 被引量：1
  • 4张永珍,高炜.氯吡格雷抵抗的机制与对策[J].中华内科杂志,2006,45(3):250-252. 被引量：12
  • 5黄震华.氯吡格雷抵抗[J].中国新药与临床杂志,2007,26(9):695-698. 被引量：7
  • 6CUISSET T, CAYLA G, SILVAIN J. Clopidogrel resistance: What's new? [J]. Arch Cardiovasc Dis, 2010, 103 (6/7): 349 - 353.
  • 7NGUYEN T A, DIODATI J G, PHARAND C. Resistance to elopi- dogrel: a review of the evidence[ J]. J Am Coll Cardiol, 2005, 45 (8) : 1157 -1164.
  • 8SEREBRUANY V L, STEINHUBL S R, BERGER P B, et al. Variability in platelet responsiveness to elopidogrel among 544 in- dividuals[J]. J Am Coll Cardiol, 2005,45(2) : 246 -251.
  • 9VERSCHUREN J J, BODEN H, WESSELS J A, et al. Value of platelet phammcogenetics in common clinical practice of patients with ST- segment elevation myocardial infarction[ J]. Int J Cardi- ol, 2013, 167(6) : 2882 -2888.
  • 10TOUSOULIS D, SIASOS G, ZAROMITIDOU M, et al. The im- pact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopi- dogrel[J]. Int J Cardiol, 2013, 168(2) : 1594 - 1596.

引证文献5

二级引证文献28

国际检验医学杂志
2013年 第15期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部